Completed PHASE2 INTERVENTIONAL 1-arm NCT00484276

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma (NGR010)

NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen

Sponsor: AGC Biologics S.p.A.

Conditions Malignant Pleural Mesothelioma

Interventions NGR-hTNF

Updated 8 times since 2017 Last updated: Jan 14, 2019 Started: May 31, 2007 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Malignant Pleural Mesothelioma, this trial is completed. The trial is conducted by AGC Biologics S.p.A. and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2020 — Jan 2021 [monthly]

Completed PHASE2
Feb 2019 — Dec 2020 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Nov 2018 — Feb 2019 [monthly]

Completed PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AGC Biologics S.p.A.

Data source: AGC Biologics S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milan, Italy
• Rozzano, Italy